Rheumatology最新文献

{"title":"Efficacy of IL-23 inhibitors in axial involvements of chronic non-bacterial osteitis with palmoplantar pustulosis: a case series.","authors":"Hirotaka Yamamoto, Yoshinori Taniguchi, Shigeyoshi Tsuji, Philip S Helliwell, Mitsumasa Kishimoto","doi":"10.1093/rheumatology/keaf088","DOIUrl":"10.1093/rheumatology/keaf088","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"4081-4083"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial.","authors":"Duvuru Geetha, Christian Pagnoux, Sebastian E Sattui, Peter A Merkel, Maria Weiner, Juliana Draibe, Stanislas Faguer, Sarah Bray, Rachel E Gurlin, Monica Balcells-Oliver, Annette Bruchfeld, David R Jayne","doi":"10.1093/rheumatology/keaf122","DOIUrl":"10.1093/rheumatology/keaf122","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the efficacy and safety of avacopan in patients aged ≥65 years with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the phase 3 ADVOCATE trial of avacopan vs a prednisone taper, plus either rituximab or cyclophosphamide.</p><p><strong>Methods: </strong>In this descriptive, post hoc analysis, patients receiving avacopan or a prednisone taper were stratified by age. Key efficacy outcomes included the rate of remission at week 26 and sustained remission at week 52.</p><p><strong>Results: </strong>Of 160 patients aged ≥65, 109 were aged 65-74 and 51 were ≥75. Remission at week 26 was achieved in 71.7% vs 69.4% of patients aged 65-74 and 73.1% vs 72.0% aged ≥75 in the avacopan vs prednisone taper groups, respectively. Sustained remission at week 52 was observed in 65.0% vs 55.1% of patients aged 65-74 and 65.4% vs 56.0% aged ≥75. Relapse rates in the avacopan vs prednisone taper groups were 12.3% vs 18.8% and 3.8% vs 20.8% in the 65-74 and ≥75 subgroups, respectively. Improvements in estimated glomerular filtration rate and health-related quality of life were observed in both treatment groups. Use of avacopan compared with a prednisone taper was associated with a 61% and 49% reduction in mean glucocorticoid dose in the 65-74 and ≥75 subgroups, respectively, and lower glucocorticoid toxicity. The proportions of patients with adverse events were similar between treatment groups within each age subgroup.</p><p><strong>Conclusion: </strong>These data support the efficacy and safety of an avacopan-based regimen to treat patients with GPA or MPA aged ≥65.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3863-3871"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs.","authors":"Sizheng Steven Zhao, Stephanie R Harrison, Ben Thompson, Max Yates, Joe Eddison, Antoni Chan, Nick Clarke, Nadia Corp, Charlotte Davis, Lambert Felix, Kalveer Flora, William J Gregory, Gareth T Jones, Christopher A Lamb, Helena Marzo-Ortega, Daniel J Murphy, Harry Petrushkin, Virinderjit Sandhu, Raj Sengupta, Stefan Siebert, Danielle A Van Der Windt, Dale Webb, Zenas Z N Yiu, Karl Gaffney","doi":"10.1093/rheumatology/keaf090","DOIUrl":"10.1093/rheumatology/keaf090","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3234-3241"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vasculitis associated with VEXAS syndrome.","authors":"Megan M Sullivan, Carolyn Mead-Harvey, Julio C Sartori-Valinotti, Kambiz Kalantari, Yael N Kusne, Mrinal M Patnaik, Abhishek A Mangaonkar, Ronald S Go, Daniel Montes, Kaaren K Reichard, Horatiu Olteanu, Melanie C Bois, Alexander S Hines, Kenneth J Warrington, Matthew J Koster","doi":"10.1093/rheumatology/keae550","DOIUrl":"10.1093/rheumatology/keae550","url":null,"abstract":"<p><strong>Objectives: </strong>To define the prevalence, distribution and characteristics of patients with VEXAS (vacuoles, E1-enzyme, X-linked, autoinflammation, somatic) syndrome who have confirmed vasculitis.</p><p><strong>Methods: </strong>Patients with VEXAS syndrome, verified by positive UBA1 mutation, were included. Chart review was performed to identify patient characteristics and outcomes. Vasculitis diagnosis was based on either histopathology showing vascular inflammation or non-invasive angiography findings. Summary statistics were calculated.</p><p><strong>Results: </strong>Eighty-nine patients met inclusion criteria. All were male with a median age of onset of 66.9 years (interquartile range 60.1, 72.7). Median (interquartile range) follow-up was 3.8 (2.2-5.5) years, during which 21 patients (23.6%) had evidence of vasculitis. Vasculitis subtypes included small vessel vasculitis (19.1%), cutaneous medium vessel vasculitis (2.2%) and large vessel vasculitis (2.2%). No patient had more than one vessel size involved. Histopathology in small vessel vasculitis patients was consistent with cutaneous leukocytoclastic vasculitis in the majority, though one patient had leukocytoclastic peritubular capillaritis on renal biopsy. Cranial symptoms (headache, vision changes or jaw pain) were noted in 18.0%. Two additional patients not experiencing cranial symptoms exhibited large vessel involvement with confirmed carotid thickening on non-invasive angiography; one of these had a positive temporal artery biopsy.</p><p><strong>Conclusion: </strong>VEXAS syndrome manifests as a variable vessel vasculitis in a quarter of patients, with cutaneous small and medium vessel involvement being particularly common. Some patients may have positive ANCA serologies or even renal vasculitis leading to misdiagnosis. Cranial symptoms are common and may mimic GCA, though documented large vessel inflammation is rare.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3889-3894"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can treatment expectations or treatment itself in patients with arthralgia suspicious for progression to rheumatoid arthritis improve illness perceptions?","authors":"Simonetta R G van Griethuysen, Quirine A Dumoulin, Elise van Mulligen, Annette H M van der Helm-van Mil","doi":"10.1093/rheumatology/keaf095","DOIUrl":"10.1093/rheumatology/keaf095","url":null,"abstract":"<p><strong>Objectives: </strong>Negative illness perceptions (IPs) are associated with poorer disease outcomes in rheumatoid arthritis (RA). Unfortunately, IPs are generally stable in established RA. We hypothesized that IPs, especially in the cognitive domain, are modifiable in arthralgia at risk of RA. We aimed to study if receiving DMARD treatment, or the offer of DMARD treatment associates with more positive IPs in patients with clinically suspect arthralgia (CSA).</p><p><strong>Methods: </strong>The population studied were CSA patients to which a wait-and-see approach was adopted without offering DMARD treatment, or patients were offered DMARD treatment via the TREAT EARLIER trial and subsequently randomized to receive methotrexate or placebo. IPs were assessed using the Brief Illness Perception Questionnaire (BIPQ), covering cognitive, emotional and comprehensibility domains. The effect of DMARD treatment on IPs over time was studied by comparing the 2-year course of BIPQs of patients receiving methotrexate or placebo. The effect of offering DMARD treatment was examined by comparing the BIPQs of CSA patients in the trial with those undergoing a wait-and-see policy.</p><p><strong>Results: </strong>In total, 375 CSA patients were studied, of which 236 of the TREAT EARLIER trial and 139 with a wait-and-see approach. Patients who received treatment showed sustained improvements in IPs over time compared with placebo in four cognitive domains: experience of physical complaints (P = 0.040), the illness's influence on life (P = 0.001), treatment effectiveness (P = 0.041) and disease duration (P = 0.045). Comparison at baseline showed that CSA patients to whom treatment was offered had more confidence in treatment (P < 0.001) and tended to have a deeper understanding of their disease (P = 0.054).</p><p><strong>Conclusion: </strong>Both the prospect of and DMARD treatment itself improved IPs in CSA, mainly in cognitive domains. These data suggest CSA as a suitable time period for influencing IPs, which may provide possibilities to improve disease outcomes in patients developing RA.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3444-3450"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143410403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shorter reproductive time span and early menopause increase the risk of ACPA-negative inflammatory arthritis in postmenopausal women with clinically suspect arthralgia.","authors":"Judith W Heutz, Anna M P Boeren, Stijn Claassen, Elise van Mulligen, Pascal H P de Jong, Annette H M van der Helm-van Mil","doi":"10.1093/rheumatology/keaf083","DOIUrl":"10.1093/rheumatology/keaf083","url":null,"abstract":"<p><strong>Objectives: </strong>The drop in oestrogen levels during menopause coincides with the peak incidence of rheumatoid arthritis (RA) in women, suggesting a role of oestrogens in its pathophysiology. However, the timing of the effect of oestrogens during RA development is unknown. Studies in the final phase of RA development, from clinically suspect arthralgia (CSA) towards clinically apparent arthritis, are lacking. We hypothesized that shorter lifetime oestrogen exposure might be associated with a higher risk of inflammatory arthritis (IA) development in women with CSA and studied this in two cohorts.</p><p><strong>Methods: </strong>Consecutively included women from two independent CSA cohorts, including a total of 433 patients, were prospectively studied. Time to inflammatory arthritis (IA) and RA development was compared for pre- vs postmenopausal women and, in postmenopausal women, for three measures of lifetime duration of oestrogen exposure: number of reproductive years, number of ovulatory years and early menopause. Analyses were stratified for ACPA status.</p><p><strong>Results: </strong>Postmenopausal women, compared with premenopausal women, had an increased risk for ACPA-negative IA (HR 2.9, 95%CI 1.05-8.0) but not for ACPA-positive IA (HR 0.8, 95%CI 0.4-1.9). Results were similar for RA development. Furthermore, early onset of menopause (HR 11.1, 95%CI 2.4-51.1), lower number of reproductive years (HR per 1 year increase 0.88, 95%CI 0.78-0.99), and lower number of ovulatory years (HR per 1 year increase 0.88, 95%CI 0.78-0.99) increased the risk of ACPA-negative IA, but not ACPA-positive IA.</p><p><strong>Conclusion: </strong>In patients with arthralgia at risk for RA, lifetime exposure to oestrogens and/or the drop in oestrogen levels after menopause might play a role in the pathophysiology of ACPA-negative RA.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3451-3457"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Fcy receptor expression augments pro-inflammatory macrophage phagocytosis in systemic sclerosis and associated rheumatic diseases.","authors":"Amela Hukara, Gino A Bonazza, Tracy Tabib, Raphael Micheroli, Suzana Jordan, Kristina Bürki, Michal Rudnik, Adrian Ciurea, Oliver Distler, Robert Lafyatis, Przemysław Błyszczuk, Gabriela Kania","doi":"10.1093/rheumatology/keae688","DOIUrl":"10.1093/rheumatology/keae688","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the pro-phagocytic phenotype of macrophages in SSc and other rheumatic diseases by examining their activation, signalling pathways and treatment responses, with the goal of uncovering mechanisms that drive enhanced phagocytosis.</p><p><strong>Methods: </strong>Single-cell RNA sequencing (scRNA-seq) datasets (GSE138669/GSE212109) from skin and lung macrophages of healthy controls (HC) and SSc patients were analysed. Human monocyte-derived macrophages (hMDMs) were differentiated from CD14+ monocytes from HC, SSc, RA, PsA, and axSpA patients. In selected experiments, hMDMs were pretreated with 0.1 μM nintedanib. Phagocytic activity was quantified using pHrodo bioparticles and flow cytometry. Macrophage surface markers were evaluated by flow cytometry, NF-κB signalling by Western blot and gene expression by RT-qPCR.</p><p><strong>Results: </strong>Analysis of scRNA-seq datasets revealed a pro-phagocytic signature in SSc-affected organs. SSc macrophages, particularly the FCGR3Ahi cluster in skin, exhibited elevated expression of FCGR genes and enriched FcγR-mediated phagocytosis pathways, accompanied by pro-inflammatory markers. This phenotype extended to FCN1hi lung macrophages in SSc patients with interstitial lung disease, indicating a systemic pro-inflammatory and phagocytic profile. hMDMs from SSc, RA and PsA patients demonstrated enhanced phagocytic activity in vitro. Elevated FcγRI and FcγRII levels were identified as key drivers of increased phagocytic activity and subsequent IL-6-driven inflammation. Nintedanib showed reduction in FcγRI expression, suggesting its potential therapeutic benefit in attenuating the phagocytic process.</p><p><strong>Conclusion: </strong>This study highlights FcγR-expressing macrophages as drivers of phagocytosis and inflammatory responses in SSc. Dysregulated activation of these macrophages could lead to persistent inflammation and fibrosis in rheumatic diseases, highlighting new potential therapeutic approaches.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3975-3988"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis.","authors":"Christopher P Denton, Otylia Kowal-Bielecka, Susanna M Proudman, Marzena Olesińska, Margitta Worm, Nicoletta Del Papa, Marco Matucci-Cerinic, Jana Radewonuk, Jeanine Jochems, Adrian Panaite, Amgad Shebl, Anna Krupa, Yannick Allanore, Jutta H Hofmann, Maria J Gasior","doi":"10.1093/rheumatology/keaf066","DOIUrl":"10.1093/rheumatology/keaf066","url":null,"abstract":"<p><strong>Objectives: </strong>The primary objective was the safety of s.c. immunoglobulin, IgPro20 (Hizentra, CSL Behring) in adults with dcSSc. Secondary objectives included pharmacokinetics and relative bioavailability of IgPro20, and safety and pharmacokinetics of IVIG, IgPro10 (Privigen, CSL Behring).</p><p><strong>Methods: </strong>In this prospective, multicentre, randomized, open-label, crossover phase 2 study (NCT04137224), patients (aged ≥18 years) with dcSSc were assigned to 16 weeks of IgPro20 (0.5 g/kg/week) followed by 16 weeks of IgPro10 (2 g/kg/4 weeks over two to five sessions), or vice versa. Treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), infusion site reactions (ISRs), clinical tests, pharmacokinetic and bioavailability were assessed.</p><p><strong>Results: </strong>Twenty-seven patients were randomized from 9 October 2019 to 31 August 2021. In total, 22 patients (81.5%) experienced 107 TEAEs (IgPro20, 49; IgPro10, 58); most were mild/moderate. Six patients (22.2%) experienced 10 SAEs (IgPro20, 6; IgPro10, 4); no treatment-related SAEs and no deaths were reported. IgPro20 ISR rate was low (2 per 100 infusions). Maximum IgG concentration [mean (s.d.)] was numerically lower following IgPro20 [23.7 (1.2) g/l] vs IgPro10 [46.1 (1.2) g/l], as was the geometric mean dose-normalized, baseline-corrected area under the concentration-time curve from time point 0 to tau [IgPro20, 44.8 (1.4) h*g/l; IgPro10, 60.2 (1.4) h*g/l]. The bioavailability of IgPro20 relative to IgPro10 was 76.1%.</p><p><strong>Conclusion: </strong>This study shows that in patients with dcSSc, safety, pharmacokinetic and bioavailability profiles of IgPro20, and safety and pharmacokinetics of IgPro10, are similar to those observed in other approved indications.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, https://clinicaltrials.gov, NCT04137224.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3657-3666"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of patient- and hospital-level predictors with patterns of initial treatment in patients with rheumatoid arthritis: findings from a national cohort study.","authors":"Zijing Yang, Edward Alveyn, Mark Russell, Katie Bechman, Callum Coalwood, Elizabeth Price, Abhishek Abhishek, Sam Norton, James Galloway","doi":"10.1093/rheumatology/keae717","DOIUrl":"10.1093/rheumatology/keae717","url":null,"abstract":"<p><strong>Objectives: </strong>To update the first-line conventional synthetic DMARDs (csDMARDs) prescribing pattern, describe change and variation across demographical and geographical factors in the RA population, and identify individual and hospital factors associated with it.</p><p><strong>Methods: </strong>This retrospective cohort study included newly diagnosed RA adult patients from 1 May 2018 to 1 April 2023 in the UK. We used adjusted multinomial logistic regression with random effect to explore associations with different first-line csDMRAD prescription and to account for hospital-level clustering.</p><p><strong>Results: </strong>We identified 15 462 RA patients who received csDMARD treatment. Overall, 57% received MTX monotherapy and 14% received MTX combination therapy as first-line treatment. MTX is the most frequently medication, following by HCQ and SSZ. Compared with non-MTX prescription, prescription of MTX monotherapy [adjusted odds ratio (aOR) 1.25 95% CI (1.22-1.29)] and MTX combination therapy [aOR 1.45 (1.38-1.52)] was significantly higher in patients with higher DAS28, but lower in the non-White individuals with comorbidities: lung disease, cancer, fracture and heart attack. Among those who received MTX, monotherapy is more likely be prescribed in patients with higher DAS28 [aOR 1.08 (1.05-1.11)] and without lung disease [aOR 0.5 (0.44-0.56)], compared with combination therapy. Around 20% of the variability in first-line csDMARD prescribing was attributed to the hospital level.</p><p><strong>Conclusion: </strong>In this cohort study of new-onset RA population, both individual- and institution-level variation in first-line csDMARD treatment strategy was evident. Gender, ethnicity, disease activity, and comorbidities, especially lung disease, were associated with disparities at the individual level.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3379-3387"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of an online, lifestyle intervention programme on the lives of patients with a rheumatic and musculoskeletal disease: a pilot study.","authors":"Kim van Slingerland, Laura J C Kranenburg, Nathalie Wilmsen, Emma Coles, Radboud J E M Dolhain, Pascal H P de Jong","doi":"10.1093/rheumatology/keae696","DOIUrl":"10.1093/rheumatology/keae696","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the short- and long-term effects of an online, interactive, multifactorial lifestyle intervention programme (Leef! Met Reuma) on health risk and all ICHOM-recommended patient-reported outcome measures (PROMs) in patients with an inflammatory arthritis (IA), osteoarthritis (OA) or fibromyalgia (FM).</p><p><strong>Methods: </strong>Patients with an IA, OA or FM could register for the lifestyle intervention programme. The programme consists of a 3-month intensive part followed by a 21-month aftercare period and focuses on four pillars, namely nutrition, exercise, relaxation and sleep. Health risk and PROMs are collected 3-monthly during the first 6 months and 6-monthly during the next 18 months. Health risk includes self-reported weight, waist circumference and BMI. Following PROMs were included: pain, morning stiffness severity, fatigue, Health Assessment Questionnaire, quality of life, perceived stress, sleep disturbance and impact on life. Descriptive statistics were used to assess the change in health risk and PROMs during the intensive part of the programme and aftercare period.</p><p><strong>Results: </strong>Of the 264 patients studied, 88, 105 and 71 were diagnosed with IA, OA and FM, respectively. Health risk significantly improved in all three diagnosis groups during the intensive part of the programme. The mean BMI reduction was -1.36 (0.26), -1.22 (0.23) and -1.48 (0.33), whereafter it stabilized in the aftercare period. All PROMs showed a similar trend.</p><p><strong>Conclusion: </strong>An online, interactive lifestyle intervention programme has a positive long-term effect, even after 2 years of follow-up, on health risk and all PRO domains in patients with an IA, OA and FM.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3309-3318"},"PeriodicalIF":4.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}